Two gene ther­a­py ap­provals head­line CBER’s FY 2018 re­port

The FDA Cen­ter for Bi­o­log­ics Eval­u­a­tion and Re­search (CBER) on Wednes­day pub­lished its fis­cal year 2018 re­port, high­light­ing two gene ther­a­py ap­provals, as well as the ap­provals of a he­pati­tis B vac­cine, a vac­cine to pre­vent shin­gles and a flu vac­cine for chil­dren as young as six months.

Both of the gene ther­a­py ap­provals oc­curred at the very be­gin­ning of the pre­vi­ous fis­cal year, with CBER sign­ing off on Spark Ther­a­peu­tics’ Lux­tur­na (voreti­gene nepar­vovec-rzyl) for chil­dren and adult pa­tients with an in­her­it­ed form of vi­sion loss in De­cem­ber 2017 and Gilead’s Yescar­ta (axi­cab­ta­gene ciloleu­cel), a cell-based gene ther­a­py, to treat adult pa­tients with cer­tain types of large B-cell lym­phoma, in Oc­to­ber 2017.

“FY 2018 was par­tic­u­lar­ly ex­cit­ing be­cause of the pace of progress in cel­lu­lar and gene ther­a­pies. CBER re­ceived more than 150 INDs for gene ther­a­py prod­ucts, bring­ing the to­tal num­ber of ac­tive INDs up to near­ly 800 ap­pli­ca­tions,” CBER Di­rec­tor Pe­ter Marks said.

Pe­ter Marks

CBER’s Of­fice of Tis­sues and Ad­vanced Ther­a­pies al­so re­leased 10 new guid­ance doc­u­ments in 2018, in­clud­ing six new draft guid­ance doc­u­ments on gene ther­a­py and a re­cent­ly fi­nal­ized guid­ance on ex­pe­dit­ed pro­grams for re­gen­er­a­tive med­i­cine.

The cen­ter al­so launched a new pro­gram in 2018, known as IN­TER­ACT, where­by spon­sors can seek a pre­lim­i­nary and in­for­mal con­sul­ta­tion with the agency pri­or to a pre-IND meet­ing.

In ad­di­tion, CBER met its drug and med­ical de­vice user fee goals and au­tho­rized the first two donor screen­ing tests for the di­rect de­tec­tion of Zi­ka virus RNA in hu­man plas­ma from in­di­vid­ual donors.

An­oth­er high­light was CBER’s grant­i­ng of an emer­gency use au­tho­riza­tion last Ju­ly to the De­part­ment of De­fense to en­able the emer­gency use of a freeze-dried plas­ma prod­uct man­u­fac­tured by the Cen­tre de Trans­fu­sion San­guine des Ar­mées (French FDP). The prod­uct is used to treat he­m­or­rhage or co­ag­u­lopa­thy of US mil­i­tary per­son­nel in­jured dur­ing com­bat when plas­ma is not avail­able, or its use is not prac­ti­cal. The move fol­lows the Pen­ta­gon’s crit­i­cism of the FDA’s slug­gish­ness in ap­prov­ing the freeze-dried prod­uct, which some said oth­er coun­tries’ troops had used for years.

As part of the FDA’s mu­tu­al recog­ni­tion agree­ments with Eu­rope, CBER as­sessed reg­u­la­tors from 14 coun­tries to en­sure their in­spec­tion of med­ical prod­ucts reg­u­lat­ed by the cen­ter could be rec­og­nized by the FDA. And CBER said it’s con­tin­u­ing to as­sess the re­main­ing EU mem­ber states to meet its 15 Ju­ly com­mit­ment that all mem­ber states are con­firmed.

What the re­port does not men­tion, how­ev­er, is the grow­ing num­ber of Re­gen­er­a­tive Med­i­cine Ad­vanced Ther­a­py (RMAT) des­ig­na­tion re­quests that the FDA is re­ceiv­ing. Ac­cord­ing to da­ta as of 31 March, there have now been 97 des­ig­na­tion re­quests (in­clud­ing 19 in the first three months of this year), of which 33 have been grant­ed, 53 de­nied and five with­drawn.

CBER FY 2018 Re­port


First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.

Author

Zachary Brennan

managing editor, RAPS

Brian Kaspar. AveXis via Twitter

AveX­is sci­en­tif­ic founder fires back at No­var­tis CEO Vas Narasimhan, 'cat­e­gor­i­cal­ly de­nies any wrong­do­ing'

Brian Kaspar’s head was among the first to roll at Novartis after company execs became aware of the fact that manipulated data had been included in its application for Zolgensma, now the world’s most expensive therapy.

But in his first public response, the scientific founder at AveXis — acquired by Novartis for $8.7 billion — is firing back. And he says that not only was he not involved in any wrongdoing, he’s ready to defend his name as needed.

I reached out to Brian Kaspar after Novartis put out word that he and his brother Allen had been axed in mid-May, two months after the company became aware of the allegations related to manipulated data. His response came back through his attorneys.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,700+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Pay­back? An­a­lysts say Sarep­ta was blind­sided by an FDA re­jec­tion dri­ven by reg­u­la­to­ry re­venge

In one of the least anticipated moves of the year, the FDA has rejected Sarepta’s application for an accelerated approval of its Duchenne MD drug golodirsen after fretting over safety issues.

In a statement that arrived after the bell on Monday, Sarepta explained the CRL, saying:

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,700+ biopharma pros reading Endpoints daily — and it's free.

FDA de­ci­sion on Ver­tex's CF triple will come just ahead of planned CEO shake­up

Vertex has clinched a priority review for the all-important cystic fibrosis triple that will blaze the trail for treating a large group of patients unhelped by its current drugs.

FDA regulators have set a PDUFA date of March 19, 2020, just a year after the Boston biotech posted positive Phase III results showing that people with two F508del mutations experienced statistically significant improvements in lung function after a 4-week regimen of VX-445, tezacaftor and ivacaftor. After reviewing 24-week data among patients with one F508del mutation and one minimal function mutation — and thoroughly comparing the VX-445 triple with another combo featuring VX-659 on scores like safety, drug-drug interactions, and photosensitivity — Vertex ultimately went with VX-445.

An MIT spin­out kills one of its ‘liv­ing ther­a­peu­tics’ af­ter flunk­ing an ear­ly-stage study — shares rout­ed

Just a few weeks after bagging $80 million in a deal to collaborate with Gingko Bioworks on its special blend of engineered bacteria used for “living therapeutics,” little Synlogic in Boston $SYBX is tossing one of its two clinical programs after watching an early-stage study go down in defeat.

Their Phase Ib/IIa study for SYNB1020 to counter the accumulation of ammonia in the body, a condition called hyperammonemia or urea cycle disorder, floundered at the interim readout, forcing the biotech to kill it and reserve its cash for pipeline therapies with greater potential.

Elan­co to buy Bay­er's an­i­mal health busi­ness for $7.6B, as deal­mak­ing gath­ers steam in the sec­tor

Last week, Elanco explicitly dodged answering questions about its rumored interest in Bayer’s animal health business in its post-earnings call. On Tuesday, the Eli Lilly spinoff disclosed it was purchasing the German drug maker’s veterinary unit in a cash-and-stock deal worth $7.6 billion. 

Elanco $ELAN has been busy on the deal-making front. In April, it laid out plans to swallow its partner, Kansas-based pet therapeutics company Aratana $PETX. A July report by Reuters suggested a potential Bayer deal was being explored, and Bloomberg last week said the deal was imminent, citing sources. 

As­traZeneca's di­a­betes drug Farx­i­ga helps pa­tients with heart dis­ease and with­out di­a­betes in land­mark tri­al

Months ago, data on J&J’s $JNJ Invokana indicated the diabetes drug conferred cardiovascular (CV) benefit in patients who do and do not have preexisting CV disease. On Tuesday, AstraZeneca’s $AZN rival treatment, Farxiga, was shown to cut the risk of CV death or the worsening of heart failure in patients with heart disease, in a landmark trial.

The treatments, in addition to Jardiance from Eli Lilly $LLY, belong to a class of diabetes drugs called sodium-glucose co-transporter 2 (SGLT2) inhibitors, which work by curbing the absorption of glucose via the kidneys so that surplus glucose is excreted through urination.

Levi Garraway. Broad Institute via Youtube

Roche raids Eli Lil­ly for its next chief med­ical of­fi­cer as San­dra Horn­ing plans to step down

We found out Monday morning where Levi Garraway was headed after he left Eli Lilly as head of oncology R&D a few days ago. Roche named Garraway as their new chief medical officer, replacing Sandra Horning, who they say is retiring from the company.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,700+ biopharma pros reading Endpoints daily — and it's free.

Af­ter a posse of Wall Street an­a­lysts pre­dict a like­ly new win for Sarep­ta, we're down to the wire on a crit­i­cal FDA de­ci­sion

As Bloomberg notes, most of the Wall Street analysts that cover Sarepta $SRPT are an upbeat bunch, ready to cheer on the team when it comes to their Duchenne MD drugs, or offer explanations when an odd setback occurs — as happened recently with a safety signal that was ‘erroneously’ reported last week.

Ritu Baral Cowen
Endpoints News

Basic subscription required

Unlock this story instantly and join 57,700+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: No­var­tis spin­off Nabri­va fi­nal­ly scores its first an­tibi­ot­ic ap­proval

In May, Nabriva Therapeutics suffered a setback after the FDA rejected its antibiotic for complicated urinary tract infections — the Novartis spinoff has now had some better luck with the US agency, which on Monday approved its other drug for community-acquired bacterial pneumonia.

The drug, lefamulin, has been developed as an intravenous and oral formulation and been tested in two late-stage clinical trials. The semi-synthetic compound, whose dosing can be switched between the two formulations, is engineered to inhibit the synthesis of bacterial protein by binding to a part of the bacterial ribosome.